Literature DB >> 9710953

Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase.

N Allon1, L Raveh, E Gilat, E Cohen, J Grunwald, Y Ashani.   

Abstract

Human butyrylcholinesterase (HuBChE) has previously been shown to protect mice, rats, and monkeys against multiple lethal toxic doses of organophosphorus (OP) anticholinesterases that were challenged by i.v. bolus injections. This study examines the concept of using a cholinesterase scavenger as a prophylactic measure against inhalation toxicity, which is the more realistic simulation of exposure to volatile OPs. HuBChE-treated awake guinea pigs were exposed to controlled concentration of soman vapors ranging from 417 to 430 micrograms/liter, for 45 to 70 s. The correlation between the inhibition of circulating HuBChE and the dose of soman administered by sequential i.v. injections and by respiratory exposure indicated that the fraction of the inhaled dose of soman that reached the blood was 0.29. HuBChE to soman molar ratio of 0.11 was sufficient to prevent the manifestation of toxic signs in guinea pigs following exposure to 2.17x the inhaled LD50 dose of soman (ILD50, 101 micrograms/kg). A slight increase in HuBChE:soman ratio (0.15) produced sign-free animals after two sequential respiratory exposures with a cumulative dose of 4.5x ILD50. Protection was exceptionally high and far superior to the currently used traditional approach that consisted of pretreatment with pyridostigmine and postexposure combined administration of atropine, benactyzine, and an oxime reactivator. Quantitative analysis of the results suggests that in vivo sequestration of soman, and presumably other OPs, by exogenously administered HuBChE, is independent of the species used or the route of challenge entry. This assuring conclusion significantly expands the database of the bioscavenger strategy that now offers a dependable extrapolation from animals to human.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710953     DOI: 10.1006/toxs.1998.2463

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  9 in total

1.  Aerosolized recombinant human butyrylcholinesterase delivered by a nebulizer provides long term protection against inhaled paraoxon in macaques.

Authors:  Yvonne Rosenberg; James Fink; Ronan MacLoughlin; Tara Ooms-Konecny; Dennis Sullivan; William Gerk; Lingjun Mao; Xiaoming Jiang; Jonathan Lees; Lori Urban; Narayanan Rajendran
Journal:  Chem Biol Interact       Date:  2019-06-12       Impact factor: 5.192

Review 2.  Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs.

Authors:  Yvonne Rosenberg; Ashima Saxena
Journal:  Neuropharmacology       Date:  2020-05-19       Impact factor: 5.250

3.  LARGE SCALE PURIFICATION OF BUTYRYLCHOLINESTERASE FROM HUMAN PLASMA SUITABLE FOR INJECTION INTO MONKEYS; A POTENTIAL NEW THERAPEUTIC FOR PROTECTION AGAINST COCAINE AND NERVE AGENT TOXICITY.

Authors:  Oksana Lockridge; Lawrence M Schopfer; Gail Winger; James H Woods
Journal:  J Med Chem Biol Radiol Def       Date:  2005-07-01

4.  Post-exposure therapy with recombinant human BuChE following percutaneous VX challenge in guinea-pigs.

Authors:  Helen Mumford; John K Troyer
Journal:  Toxicol Lett       Date:  2011-05-19       Impact factor: 4.372

5.  Development of a long-acting Fc-fused cocaine hydrolase with improved yield of protein expression.

Authors:  Xiabin Chen; Jing Deng; Xirong Zheng; Jinling Zhang; Ziyuan Zhou; Huimei Wei; Chang-Guo Zhan; Fang Zheng
Journal:  Chem Biol Interact       Date:  2019-04-12       Impact factor: 5.192

6.  Intrathecal delivery of fluorescent labeled butyrylcholinesterase to the brains of butyrylcholinesterase knock-out mice: visualization and quantification of enzyme distribution in the brain.

Authors:  Noel D Johnson; Ellen G Duysen; Oksana Lockridge
Journal:  Neurotoxicology       Date:  2009-03-20       Impact factor: 4.294

7.  Identification and Study of Biomarkers from Novichok-Inhibited Butyrylcholinesterase in Human Plasma.

Authors:  Woo-Hyeon Jeong; Jin-Young Lee; Kyoung-Chan Lim; Hyun-Suk Kim
Journal:  Molecules       Date:  2021-06-22       Impact factor: 4.411

8.  Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin.

Authors:  Yue-Jin Huang; Paul M Lundy; Anthoula Lazaris; Yue Huang; Hernan Baldassarre; Bin Wang; Carl Turcotte; Mélanie Côté; Annie Bellemare; Annie S Bilodeau; Sandra Brouillard; Madjid Touati; Peter Herskovits; Isabelle Bégin; Nathalie Neveu; Eric Brochu; Janice Pierson; Duncan K Hockley; Douglas M Cerasoli; David E Lenz; Harvey Wilgus; Costas N Karatzas; Solomon Langermann
Journal:  BMC Biotechnol       Date:  2008-05-16       Impact factor: 2.563

9.  Sodium Ion Effect on Separation Of Butyrylcholinesterase from Plasma by Ion-Exchange Chromatography.

Authors:  A G Postoarca; M Ionescu; A Piperea-Sianu; I Sarbu; L G Hinescu
Journal:  Curr Health Sci J       Date:  2015-04-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.